Belatacept is indicated for:
Prophylaxis of graft rejection in renal transplant
Irrespective of gender only Adults (18 years old or older)
Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 5-10 mg/kg
Active ingredient Belatacept is contraindicated in the following cases: